NewAmsterdam Pharma (NAMS) outlook: obicetrapib could cut cardiovascular risk beyond LDL-C. Key catalysts into 2026–27; ...

ETB's 8.15% distribution yield is attractive and tax-efficient, making it suitable for taxable accounts. Read why ETB is ...

John Paulson’s Q1 2026 13F portfolio decreased to ~$3.11B, concentrated in nine securities, with the top five making up ~87%.

Compare 12%-yielding tech lenders HTGC vs. TRIN at 1.3x NAV—pros, cons, and which fits your portfolio. Click to read more.

Unlike traditional mutual funds or ETFs, secondary market CEFs routinely decouple from true book values. Here's what you need ...

Gold Royalty (GROY) shifts to cash-flow compounding as acquisitions boost near-term revenue and long-term growth.

Taiwan Semiconductor Manufacturing is rated Buy: resilient chip leader insulated from AI price wars. See more analysis on TSM ...

Neocloud stocks after the sell-off: see why analysts favor Applied Digital (APLD) and Nebius (NBIS). Read more here.

COPX is 23% below highs despite strong copper. Explore why miners lag, key risks (China, inventories) and electrification ...

Axon Q1 beats and raises 2025 revenue growth to 30–32%, but weak FCF and cash conversion risks persist. Click to read more ...

Healthcare systems are facing rising operating pressure, thinner margins, and a harder question about how to manage liquidity ...

Howmet Aerospace (HWM) lifts guidance on 19% growth and record margins, but valuation is stretched at 55x. Read here for a ...